Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/2405/Arslan%2c%20Ferhat-2014.pdf.jpg?sequence=5&isAllowed=y)
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2014Yazar
Batirel, AyşeBalkan, İlker İnanç
Karabay, Oğuz
Ağalar, Canan
Akalın, Şerife
Alıcı, Özlem
Alp, Emine
Altay, Fatma Aybala
Altın, Nilgün
Arslan, Ferhat
Aslan, Turan
Bekiroğlu, Nuray
Cesur, Salim
Çelik, Aygül Dogan
Doğan, Mustafa
Durdu, Bülent
Duygu, Fazilet
Engin, Aynur
Engin, Derya Öztürk
Gönen, İbak
Güçlü, Ertuğrul
Güven, Tümer
Hatipoğlu, Çiğdem Ataman
Hoşoğlu, Salih
Karahocagil, Mustafa Kasım
Ulu Kılıç, Aysegül
Örmen, Bahar
Özdemir, Davut
Özer, Serdar
Öztoprak, Nefise
Sezak, Nurbanu
Turhan, Vedat
Türker, Nesrin
Yılmaz, Hava
Üst veri
Tüm öğe kaydını gösterKünye
Batirel, A., Balkan, İ. İ., Karabay, O., Ağalar, C., Akalın, Ş., Alıcı, Ö. ... Yılmaz, H. (2014). Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. European Journal of Clinical Microbiology & Infectious Diseases, 33(8), 1311-1322. https://dx.doi.org/10.1007/s10096-014-2070-6Özet
The purpose of this investigation was to compare the efficacy of colistin-based therapies in extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). A retrospective study was conducted in 27 tertiary-care centers from January 2009 to August 2012. The primary end-point was 14-day survival, and the secondary end-points were clinical and microbiological outcomes. Thirty-six and 214 patients [102 (47.7 %): colistin-carbapenem (CC), 69 (32.2 %): colistin-sulbactam (CS), and 43 (20.1 %: tigecycline): colistin with other agent (CO)] received colistin monotherapy and colistin-based combinations, respectively. Rates of complete response/cure and 14-day survival were relatively higher, and microbiological eradication was significantly higher in the combination group. Also, the in-hospital mortality rate was significantly lower in the combination group. No significant difference was found in the clinical (p = 0.97) and microbiological (p = 0.92) outcomes and 14-day survival rates (p = 0.79) between the three combination groups. Neither the timing of initial effective treatment nor the presence of any concomitant infection was significant between the three groups (p > 0.05) and also for 14-day survival (p > 0.05). Higher Pitt bacteremia score (PBS), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Charlson comorbidity index (CCI), and prolonged hospital and intensive care unit (ICU) stay before XDR-ABSI were significant risk factors for 14-day mortality (p = 0.02, p = 0.0001, p = 0.0001, p = 0.02, and p = 0.01, respectively). In the multivariable analysis, PBS, age, and duration of ICU stay were independent risk factors for 14-day mortality (p < 0.0001, p < 0.0001, and p = 0.001, respectively). Colistin-based combination therapy resulted in significantly higher microbiological eradication rates, relatively higher cure and 14-day survival rates, and lower in-hospital mortality compared to colistin monotherapy. CC, CS, and CO combinations for XDR-ABSI did not reveal significant differences with respect to 14-day survival and clinical or microbiological outcome before and after propensity score matching (PSM). PBS, age, and length of ICU stay were independent risk factors for 14-day mortality.
WoS Q Kategorisi
Q3Scopus Q Kategorisi
Q1Kaynak
European Journal of Clinical Microbiology & Infectious DiseasesCilt
33Sayı
8Koleksiyonlar
- Makale Koleksiyonu [3790]
- PubMed İndeksli Yayınlar Koleksiyonu [4251]
- Scopus İndeksli Yayınlar Koleksiyonu [6601]
- WoS İndeksli Yayınlar Koleksiyonu [6677]
İlgili Öğeler
Başlık, yazar, küratör ve konuya göre gösterilen ilgili öğeler.
-
Antibiyotik tüketimi, direnç verileri ve önlem stratejileri
Karabay, Oğuz; Baştuğ, Aliye; Öztürk, Rıfat Can; Sencan, İkbal; Aksoy, Mehmet; Şimşek, Hatice; Gözel, Mustafa Gökhan; Erdoğan, Haluk; Karlıdağ, E. G.; Aypak, Adalet; Gönen, İbak; Gürpınar, Emre; İşli, Fatma; Süzük Yıldız, Serap; Yarsan, Ender; Bodur, Hürrem (Galenos Yayıncılık, 2018)Dünyada ve ülkemizde antibiyotik tüketiminin artışına ilişkin veriler alarm vermektedir. Aşırı tüketim artan antibiyotik direncini tetiklemektedir. Ne yazık ki ülkemiz antibiyotik direncinin en fazla yaşandığı ülkelerdendir. ... -
Colistin nephrotoxicity increases with age
Balkan, İlker İnanç; Doğan, Mustafa; Durdu, Bülent; Batırel, Ayşe; Hakyemez, İsmail Necati; Çetin, Birsen; Karabay, Oğuz; Gönen, İbak; Özkan, Ahmet Selim; Uzun, Sami; Demirkol, Muhammed Emin; Akbaş, Sedat; Kaçmaz, Asiye Bahar; Aras, Sükrü; Mert, Ali; Tabak, Fehmi (Informa Healthcare, 2014)Background: Colistin (COL) has become the backbone of the treatment of infections due to extensively drug-resistant (XDR) Gram-negative bacteria. The most common restriction to its use is acute kidney injury (AKI). Methods: ... -
İntravitreal kolistin retinal toksisitesinin araştırılması
Özbek, Merve (İstanbul Medipol Üniversitesi Tıp Fakültesi, 2018)AMAÇ: Çeşitli konsantrasyonlarda kolistinin intravitreal uygulanmasının sağlıklı oküler dokular üzerindeki olası yan etkilerini ve güvenli doz aralığını belirlemek MATERYAL METOD: 20 erişkin dişi ve erkek, beyaz Yeni ...